Skip to main content
Top
Published in: The Journal of Obstetrics and Gynecology of India 3/2020

01-06-2020 | Ovarian Cancer | Original Article

Diagnostic Value of Risk of Malignancy Algorithm (ROMA) in Adnexal Masses

Authors: Vijay Kumar, Shiv Rajan, Sameer Gupta, Naseem Akhtar, Sonali Sharma, Punnet Sinha, Sanjeev Misra, Arun Chaturvedi

Published in: The Journal of Obstetrics and Gynecology of India | Issue 3/2020

Login to get access

Abstract

Background

Differentiating malignancy from benign diseases is the key to successful management of adnexal masses. Risk of malignancy algorithm (ROMA) has been used for this purpose. We have prospectively studied the diagnostic value of ROMA in patients presented with adnexal masses.

Methods

We prospective calculated ROMA values prior to surgery for adnexal masses. The risk calculated was then correlated with the histological findings, and results were analyzed according to menopausal status. ROMA cutoff value was determined using ROC curve, and sensitivity, specificity and predictive values were calculated. Statistics were performed on SPSS software (version 20.0).

Results

There were 94 patients with adnexal masses included in the study, 65 (69.1%) had epithelial ovarian cancer and 29 (30.9%) were diagnosed benign on histopathology. In both pre- and postmenopausal patients, ROMA values were significantly higher in patients with malignancy compared to those with benign disease (p < 0.05). ROMA score was of a significant diagnostic value in both premenopausal (AUC = 0.914, Z = 10.81, p < 0.001) and postmenopausal patients (AUC = 0.975, Z = 21.51, p < 0.001). In premenopausal females, ROMA > 13.3% was able to discriminate malignant from benign patients with 97.06% sensitivity and 85.00% specificity. The positive and negative predictive values were 91.7% and 94.4%. Similarly, in postmenopausal females, ROMA value of > 76% achieved 87.10% sensitivity and 100.00% specificity in discriminating malignant from benign patients with 100% positive and 69.2% negative predictive value. The overall accuracy of ROMA in pre- and postmenopausal patients was 87.0% and 85%, respectively.

Conclusions

ROMA is a useful and accurate test for differentiating epithelial ovarian cancer from benign ovarian masses. Further studies are needed to compare performance of ROMA with the Risk of Malignancy Index (RMI), CA 125 and HE4. Such comparative studies will be helpful to the clinician in deciding the best diagnostic tool for women with adnexal masses.
Literature
1.
go back to reference Pavlik EJ, Ueland FR, Miller RW, et al. Frequency and disposition of ovarian abnormalities followed with serial transvaginal ultrasonography. Obstet Gynecol. 2013;122:210–7.CrossRef Pavlik EJ, Ueland FR, Miller RW, et al. Frequency and disposition of ovarian abnormalities followed with serial transvaginal ultrasonography. Obstet Gynecol. 2013;122:210–7.CrossRef
2.
go back to reference Greenlee RT, Kessel B, Williams CR, et al. Prevalence, incidence, and natural history of simple ovarian cysts among women > 55 years old in a large cancer screening trial. Am J Obstet Gynecol. 2010;202:373.e1–9.CrossRef Greenlee RT, Kessel B, Williams CR, et al. Prevalence, incidence, and natural history of simple ovarian cysts among women > 55 years old in a large cancer screening trial. Am J Obstet Gynecol. 2010;202:373.e1–9.CrossRef
4.
go back to reference American College of Obstetricians and Gynecologists. Management of adnexal masses. ACOG Practice Bulletin No. 83. Obstet Gynecol. 2007; 110:201–214. American College of Obstetricians and Gynecologists. Management of adnexal masses. ACOG Practice Bulletin No. 83. Obstet Gynecol. 2007; 110:201–214.
5.
go back to reference du Bois A, Rochon J, Pfisterer J, et al. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. GynecolOncol. 2009;112:422–36. du Bois A, Rochon J, Pfisterer J, et al. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. GynecolOncol. 2009;112:422–36.
6.
go back to reference Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295–303.CrossRef Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295–303.CrossRef
7.
go back to reference Sturgeon CM, Duffy MJ, Stenman UH, et al. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancer. Clin Chem. 2008;54:e11–79.CrossRef Sturgeon CM, Duffy MJ, Stenman UH, et al. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancer. Clin Chem. 2008;54:e11–79.CrossRef
8.
go back to reference Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA-125 for the prediction of ovarian cancer in patients with a pelvic mass. GynecolOncol. 2009;112:40–6. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA-125 for the prediction of ovarian cancer in patients with a pelvic mass. GynecolOncol. 2009;112:40–6.
9.
go back to reference Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. ObstetGynecol. 2011;118:280–8. Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. ObstetGynecol. 2011;118:280–8.
10.
go back to reference VanGorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011;104:863–70.CrossRef VanGorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011;104:863–70.CrossRef
11.
go back to reference Chan KK, Chen CA, Nam JH, et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. GynecolOncol. 2013;28:239–44. Chan KK, Chen CA, Nam JH, et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. GynecolOncol. 2013;28:239–44.
12.
go back to reference Sandri MT, Bottari F, Franchi D, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. GynecolOncol. 2013;128:233–8. Sandri MT, Bottari F, Franchi D, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. GynecolOncol. 2013;128:233–8.
13.
go back to reference Karlsen MA, Høgdall EV, Christensen IJ, et al. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer—an international multicenter study in women with an ovarian mass. GynecolOncol. 2015;138:640–6. Karlsen MA, Høgdall EV, Christensen IJ, et al. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer—an international multicenter study in women with an ovarian mass. GynecolOncol. 2015;138:640–6.
14.
go back to reference Bandiera E, Romani C, Specchia C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496–506.CrossRef Bandiera E, Romani C, Specchia C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496–506.CrossRef
15.
go back to reference Montagnana M, Danese E, Ruzzenente O, et al. The ROMA (risk of ovarian malignancy algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? ClinChem Lab Med. 2011;49:521–5. Montagnana M, Danese E, Ruzzenente O, et al. The ROMA (risk of ovarian malignancy algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? ClinChem Lab Med. 2011;49:521–5.
16.
go back to reference Kim YM, Whang DH, Park J, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. ClinChem Lab Med. 2011;49:527–34. Kim YM, Whang DH, Park J, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. ClinChem Lab Med. 2011;49:527–34.
17.
go back to reference Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA-125 as ovarian tumor markers in a clinical setting. GynecolOncol. 2011;121:487–91. Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA-125 as ovarian tumor markers in a clinical setting. GynecolOncol. 2011;121:487–91.
Metadata
Title
Diagnostic Value of Risk of Malignancy Algorithm (ROMA) in Adnexal Masses
Authors
Vijay Kumar
Shiv Rajan
Sameer Gupta
Naseem Akhtar
Sonali Sharma
Punnet Sinha
Sanjeev Misra
Arun Chaturvedi
Publication date
01-06-2020
Publisher
Springer India
Published in
The Journal of Obstetrics and Gynecology of India / Issue 3/2020
Print ISSN: 0971-9202
Electronic ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-019-01295-3

Other articles of this Issue 3/2020

The Journal of Obstetrics and Gynecology of India 3/2020 Go to the issue